Source

,

Sector

Healthcare

Industry

Medical Instruments & Supplies

Region

Europe

Germany

Market Cap

1.300bn


Key Issues

  • Evidence of a constructed fraud shell: Anbio’s structure, addresses, products, and filings consistently fail basic verification.
  • Market manipulation indicators: Share inflation, fake investors, and dramatic stock swings point to an orchestrated pump-and-dump cycle.
  • Regulatory noncompliance risks: Misleading disclosures, nonexistent operations, and false corporate information signal potential SEC and Nasdaq violations.

Investor Takeaways

  • Anbio lacks real business substance—no facilities, no supply chain, and likely fabricated products.
  • Insider-controlled structure and suspicious investors suggest the IPO enriched a small circle at public expense.
  • Extreme price volatility is engineered, not market-driven, making the stock highly dangerous for retail investors.

We also recommend this insightful Reddit thread: Anbio Biotechnology – A Very Mysterious Company.

Entry Date

2025-09-10 11:30:00

Entry Price

45.3300

USD

Current Date

2026-01-16 21:00:00

Current Price

32.5300

USD

Close Date

Close Price

USD

Tenure

128.4 days

Performance

28.24%